Novel Vaccine Formulations for Mycobacterium Tuberculosis

Back to all technologies
Download as PDF
2019-MITT-68665
Researchers at Purdue University have developed a novel addition to traditional vaccines which includes painless intranasal delivery of an Autophagy Inducing Peptide (AIP) for directly inhibiting the root cause of the tuberculosis—Mtb. Mtb is a leading cause of death worldwide, leading to 1.5 million fatalities annually. Those highly susceptible to (Mtb), expressly at-risk seniors and children, are not completely protected by currently available preventative Bacillus Calmette Guérin vaccines. Purdue researchers have created a vaccine to allow the body's immune system to fight Mtb antigens using a mycobacterial antigen-85B, for targeting Mtb, with autophagy-inducing peptide, C5 from CFP10 proteins that contribute to virulence of Mtb, that can be expressed by a bovine adenoviral vector (BAd85C5) or a human adenoviral vector (HAd85C5). In testing in mice, the new vaccines were administered along with an intranasal aerosol-based booster. Robust effector (TEM) and central memory (TCM) T cell response was achieved with the Bad85C5 vaccine, and IL-12 expression was observed to monitor effectiveness of C5, validating an enhanced immune response in mice.

Advantages:
-Improves Pediatric Care
-Less Invasive
-Enhanced T Cell Response

Potential Applications:
-Tuberculosis Vaccine
-Vaccine approach for other infectious diseases
-Cancer Treatments
-Life Science Research

Technology Validation:
The new TB vaccine strategy was tested in mice conferring significant protection from an intranasal Mtb challenge.
Mar 12, 2021
Provisional-Gov. Funding
United States
(None)
(None)
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org